Zenocutuzumab Disease Interactions
There are 4 disease interactions with zenocutuzumab.
Zenocutuzumab (applies to zenocutuzumab) congestive heart failure
Moderate Potential Hazard, Moderate plausibility.
Zenocutuzumab can cause left ventricular dysfunction and has not been studied in patients with a history of clinically significant cardiac disease or left ventricular ejection fraction (LVEF) less than 50% prior to treatment initiation. LVEF should be evaluated prior to using this drug and monitored at regular intervals during treatment.
Zenocutuzumab (applies to zenocutuzumab) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The pharmacokinetics of zenocutuzumab have not been studied in patients with moderate to severe hepatic impairment (total bilirubin greater than 1.5 to 3 times upper limit of normal with any AST).
Zenocutuzumab (applies to zenocutuzumab) pulmonary impairment
Moderate Potential Hazard, Moderate plausibility.
Zenocutuzumab can cause interstitial lung disease (ILD) and pneumonitis. New or worsening pulmonary symptoms that can indicate ILD or pneumonitis such as dyspnea, cough, or fever, should be closely monitored.
Zenocutuzumab (applies to zenocutuzumab) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The pharmacokinetics of zenocutuzumab in patients with severe renal impairment (CrCl less than 30 mL/min) is unknown.
Switch to professional interaction data
Zenocutuzumab drug interactions
There are 92 drug interactions with zenocutuzumab.
Report options
More about zenocutuzumab
- zenocutuzumab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Fluorouracil
Fluorouracil systemic is used for anal cancer, breast cancer, breast cancer, palliative, cancer ...
Cisplatin
Cisplatin systemic is used for anal cancer, bladder cancer, blood cell transplantation, bone marrow ...
Capecitabine
Capecitabine systemic is used for anal cancer, breast cancer, breast cancer, metastatic, colorectal ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.